RLYB Rallybio Corp

Nasdaq rallybio.com


$ 0.54 $ -0.02 (-3.39 %)    

Friday, 17-Oct-2025 15:59:13 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 0.5351
$ 0.54
$ 0.50 x 200
$ 0.57 x 11,614
$ 0.53 - $ 0.55
$ 0.22 - $ 1.24
102,596
na
22.36M
$ 0.57
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-12-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-08-2023 06-30-2023 10-Q
10 05-09-2023 03-31-2023 10-Q
11 03-06-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-10-2022 03-31-2022 10-Q
15 03-15-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 09-09-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 rallybio-completes-dosing-for-first-cohort-in-phase-1-confirmatory-pkpd-study-of-rlyb116-its-once-weekly-small-volume-subcutaneous-c5-inhibitor-being-developed-to-treat-rare-diseases

Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative...

 rallybio-q2-eps-022-beats-024-estimate-sales-212000k-down-from-299000k-yoy

Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 1...

 why-is-microcap-rallybio-stock-trading-higher-on-tuesday

Rallybio sells its stake in preclinical HPP drug REV102 to Recursion in a deal worth up to $25 million, including equity and mi...

Core News & Articles

Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced th...

 rallybio-initiates-dosing-in-phase-1-confirmatory-pkpd-study-evaluating-rlyb116-subcutaneously-injected-c5-inhibitor

– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refracto...

 rallybio-q1-eps-021-beats-026-estimate-sales-21200k

Rallybio (NASDAQ:RLYB) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.26) by 1...

 jones-trading-downgrades-rallybio-to-hold

Jones Trading analyst Catherine Novack downgrades Rallybio (NASDAQ:RLYB) from Buy to Hold.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION